$2.60
0.39%
Nasdaq, Sep 12, 10:10 pm CET
ISIN
US45256X1037
Symbol
IBRX

ImmunityBio Inc Stock price

$2.60
+0.13 5.26% 1M
-0.27 9.41% 6M
+0.04 1.56% YTD
-0.89 25.50% 1Y
-3.01 53.65% 3Y
-5.49 67.86% 5Y
-14.99 85.22% 10Y
-32.04 92.49% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
+0.01 0.39%
ISIN
US45256X1037
Symbol
IBRX
Industry

Key metrics

Basic
Market capitalization
$2.5b
Enterprise Value
$3.1b
Net debt
$645.5m
Cash
$153.7m
Shares outstanding
852.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
43.4 | 22.8
EV/Sales
54.8 | 28.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-127.7%
Return on Equity
84.6%
ROCE
-81.2%
ROIC
-118.5%
Debt/Equity
-1.4
Financials (TTM | estimate)
Revenue
$56.6m | $107.6m
EBITDA
$-283.4m | -
EBIT
$-285.4m | $-286.4m
Net Income
$-367.1m | $-448.0m
Free Cash Flow
$-356.7m
Growth (TTM | estimate)
Revenue
4,220.6% | 629.7%
EBITDA
20.9% | -
EBIT
20.7% | 16.8%
Net Income
38.6% | -8.3%
Free Cash Flow
16.2%
Margin (TTM | estimate)
Gross
88.9%
EBITDA
-500.7% | -
EBIT
-504.2%
Net
-648.6% | -416.3%
Free Cash Flow
-630.2%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
25.9%
Employees
680
Rev per Employee
$20.0k
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a ImmunityBio Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a ImmunityBio Inc forecast:

Buy
91%
Hold
9%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
57 57
4,221% 4,221%
100%
- Direct Costs 0.19 0.19
-
0%
50 50
-
89%
- Selling and Administrative Expenses 153 153
2% 2%
270%
- Research and Development Expense 187 187
8% 8%
331%
-283 -283
21% 21%
-501%
- Depreciation and Amortization 2 2
0% 0%
4%
EBIT (Operating Income) EBIT -285 -285
21% 21%
-504%
Net Profit -367 -367
39% 39%
-649%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Positive
Seeking Alpha
4 days ago
I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of forward guidance raise valuation concerns despite a large market opportunity. FDA setbacks and slow Anktiva sales growth temper enthusiasm, with expansion into new indications still at an early and ...
Neutral
Business Wire
7 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced new paradigm changing findings from the Phase 2 QUILT-3.055 study, demonstrating ANKTIVA® (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC), wit...
Neutral
Business Wire
20 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with its investigational immune-boosting regimen including ANKTIVA® (nogapendekin alfa inbakicept-pmln) in this pilot study (NCT06061809). All five patients achieved 100% disease control with the regim...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 680
Founded 2014
Website immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today